Güllü Görgün

5.8k total citations
74 papers, 3.8k citations indexed

About

Güllü Görgün is a scholar working on Hematology, Molecular Biology and Immunology. According to data from OpenAlex, Güllü Görgün has authored 74 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Hematology, 43 papers in Molecular Biology and 23 papers in Immunology. Recurrent topics in Güllü Görgün's work include Multiple Myeloma Research and Treatments (38 papers), Protein Degradation and Inhibitors (19 papers) and Histone Deacetylase Inhibitors Research (11 papers). Güllü Görgün is often cited by papers focused on Multiple Myeloma Research and Treatments (38 papers), Protein Degradation and Inhibitors (19 papers) and Histone Deacetylase Inhibitors Research (11 papers). Güllü Görgün collaborates with scholars based in United States, United Kingdom and Japan. Güllü Görgün's co-authors include Kenneth C. Anderson, Francine M. Foss, Teru Hideshima, John G. Gribben, Nikhil C. Munshi, Noopur Raje, Paul G. Richardson, Kenneth B. Miller, Alan G. Ramsay and Rifca Le Dieu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Güllü Görgün

73 papers receiving 3.8k citations

Peers

Güllü Görgün
Juerg Schwaller Switzerland
Boris K. Lin United States
Kenneth H. Shain United States
Enrique M. Ocio Spain
Ruben D. Carrasco United States
Sari H. Enschede United States
Michele Moschetta United States
Sonia Vallet United States
Tetsuzo Tauchi Japan
Christine Pien United States
Juerg Schwaller Switzerland
Güllü Görgün
Citations per year, relative to Güllü Görgün Güllü Görgün (= 1×) peers Juerg Schwaller

Countries citing papers authored by Güllü Görgün

Since Specialization
Citations

This map shows the geographic impact of Güllü Görgün's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Güllü Görgün with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Güllü Görgün more than expected).

Fields of papers citing papers by Güllü Görgün

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Güllü Görgün. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Güllü Görgün. The network helps show where Güllü Görgün may publish in the future.

Co-authorship network of co-authors of Güllü Görgün

This figure shows the co-authorship network connecting the top 25 collaborators of Güllü Görgün. A scholar is included among the top collaborators of Güllü Görgün based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Güllü Görgün. Güllü Görgün is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tawbi, Hussein A., Caroline Robert, Jan C. Brase, et al.. (2022). Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). Journal for ImmunoTherapy of Cancer. 10(6). e004226–e004226. 19 indexed citations
2.
Sborov, Douglas W., Craig C. Hofmeister, James E. Bradner, et al.. (2017). Immunomodulatory Effects of HDACi in Combination with Checkpoint Blockade and Lenalidomide in the Immunosuppressive Multiple Myeloma Bone Marrow Microenvironment. Blood. 130. 4422–4422. 3 indexed citations
3.
Ohguchi, Hiroto, Teru Hideshima, Manoj Bhasin, et al.. (2016). The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival. Nature Communications. 7(1). 10258–10258. 75 indexed citations
4.
Suzuki, Rikio, Shohei Kikuchi, Takeshi Harada, et al.. (2015). Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS ONE. 10(12). e0143847–e0143847. 19 indexed citations
5.
Hideshima, Teru, Francesca Cottini, Hiroto Ohguchi, et al.. (2015). Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. Blood Cancer Journal. 5(5). e312–e312. 53 indexed citations
6.
Cirstea, Diana, Loredana Santo, Teru Hideshima, et al.. (2014). Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma. Molecular Cancer Therapeutics. 13(11). 2489–2500. 24 indexed citations
7.
Mimura, Naoya, Teru Hideshima, Toshiyasu Shimomura, et al.. (2014). Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition. Cancer Research. 74(16). 4458–4469. 66 indexed citations
8.
Cirstea, Diana, Teru Hideshima, Loredana Santo, et al.. (2013). Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 27(12). 2366–2375. 47 indexed citations
9.
Fabre, Claire, Naoya Mimura, Kathryn Bobb, et al.. (2012). Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma. Clinical Cancer Research. 18(17). 4669–4681. 66 indexed citations
10.
Görgün, Güllü & Kenneth C. Anderson. (2011). Intrinsic Modulation of Lymphocyte Function by Stromal Cell Network: Advance in Therapeutic Targeting of Cancer. Immunotherapy. 3(10). 1253–1264. 5 indexed citations
11.
Cirstea, Diana, Teru Hideshima, Scott J. Rodig, et al.. (2010). Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound –Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma. Molecular Cancer Therapeutics. 9(4). 963–975. 136 indexed citations
12.
Ikeda, Hiroshi, Teru Hideshima, Mariateresa Fulciniti, et al.. (2010). PI3K/p110δ is a novel therapeutic target in multiple myeloma. Blood. 116(9). 1460–1468. 156 indexed citations
13.
Santo, Loredana, Sonia Vallet, Teru Hideshima, et al.. (2010). AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition. Oncogene. 29(16). 2325–2336. 114 indexed citations
14.
Zahrieh, David, Güllü Görgün, Aihong Li, et al.. (2005). Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia. British Journal of Haematology. 129(4). 499–510. 37 indexed citations
15.
Miller, K B, Todd F. Roberts, Geoffrey Chan, et al.. (2004). A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. Bone Marrow Transplantation. 33(9). 881–889. 53 indexed citations
16.
Tian, Xuejun, et al.. (2002). Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene. Leukemia Research. 26(12). 1077–1083. 32 indexed citations
17.
Görgün, Güllü, et al.. (2002). Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines. Cellular Signalling. 14(4). 317–325. 49 indexed citations
18.
Urbano, Alexander, Güllü Görgün, & Francine M. Foss. (2002). Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells. Biochemical Pharmacology. 63(4). 689–692. 14 indexed citations
19.
Görgün, Güllü, et al.. (2002). ALTERED BIOLOGICAL ACTIVITY ASSOCIATED WITH C-TERMINAL MODIFICATIONS OF IL-7. Cytokine. 20(1). 17–22. 3 indexed citations
20.
Görgün, Güllü & Francine M. Foss. (2000). Induction of apoptosis in lymphoid leukemia cells: differential effects of rar and rxr retinoids with dexamethasone. Blood. 96. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Juerg Schwaller Breakdown of academic impact, for papers by Boris K. Lin Breakdown of academic impact, for papers by Kenneth H. Shain Breakdown of academic impact, for papers by Enrique M. Ocio Breakdown of academic impact, for papers by Ruben D. Carrasco Breakdown of academic impact, for papers by Sari H. Enschede Breakdown of academic impact, for papers by Michele Moschetta Breakdown of academic impact, for papers by Sonia Vallet Breakdown of academic impact, for papers by Tetsuzo Tauchi Breakdown of academic impact, for papers by Christine Pien
Rankless by CCL
2026